Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 1—January 2012
Research

Invasive Meningococcal Capsular Group Y Disease, England and Wales, 2007–2009

Shamez N. LadhaniComments to Author , Jay Lucidarme, Lynne S. Newbold, Stephen J. Gray, Anthony D. Carr, Jamie Findlow, Mary E. Ramsay, Edward B. Kaczmarski, and Raymond Borrow
Author affiliations: Health Protection Agency, London, UK (S.N. Ladhani, M.E. Ramsay); Health Protection Agency, Manchester, UK (J. Lucidarme, L.S. Newbold, S.J. Gray, A.D. Carr, J. Findlow, E.B. Kaczmarski, R. Borrow); University of Manchester, Manchester (R. Borrow)

Main Article

Table 2

Clinical presentation of, risk factors for, and outcome of patients with invasive meningococcal capsular group Y disease, England and Wales, 2007–2009

Variable Age group, y, no. (%) patients
Total, n = 65
<25, n = 20 25–64, n = 19 65–84, n = 13 >85, n = 13
Female sex 11 (55) 14 (74) 10 (77) 12 (92) 47 (72)
Travel* 2 (10) 2 (11) 1 (8) 0 5 (8)
Clinical feature
Meningitis 8 (40) 11 (58) 2 (15) 1 (8) 23 (35)
Pneumonia 1 (5) 3 (16) 5 (39) 10 (77) 19 (29)
Septicemia 10 (50) 2 (11) 4 (31) 1 (8) 17 (26)
Other 1 (5) 3 (16) 2 (15) 1 (8) 7 (11)
Underlying conditions† 3 (15) 5 (26) 7 (54) 10 (77) 25 (39)
Immune deficiency‡ 2 (10) 1 (5) 2 (15) 3 (23) 8 (12)
Sequelae§ 1 (5) 1 (5) 0 1 (8) 3 (5)
Deaths 2 (10) 1 (5) 2 (15) 7 (54) 12 (19)

*Travel-associated infection included 2 visitors from Australia and South America and 3 residents who had traveled to Jamaica and Thailand and taken a Mediterranean cruise in the preceding 4 weeks.
†Underlying medical conditions included complement deficiency (1 person), diabetes mellitus (1), and systemic lupus erythematosus among persons <25 years of age; chronic liver disease (3), diabetes mellitus (1), and rheumatoid arthritis on immunosuppressive therapy (1) among persons 25–64 years of age; malignancy undergoing chemotherapy (2), diabetes mellitus (2), chronic heart disease (2), and chronic respiratory disease (1) among persons 65–84 years of age; and chronic heart disease (7), malignancy undergoing chemotherapy (2), chronic respiratory disease (1), and rheumatoid arthritis on immunosuppressive therapy (1) among persons >85 years of age.
‡Immunodeficiency included malignancy receiving chemotherapy (4 persons), autoimmune disease requiring immunosuppressant therapy (3), and complement deficiency (1).
§Sequelae included hemiparesis after meningitis in a toddler, bilateral sensorineural deafness requiring cochlear implantat after meningitis in an adult, and chronic renal insufficiency in an elderly person with septicemia.

Main Article

Page created: January 19, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external